Eurofarma Ventures
VC Fund
São Paulo, Brazil
Eurofarma Ventures is a VC fund in São Paulo focused on Biotechnology and Life Science. Eurofarma Ventures operates as a venture capital arm of Eurofarma.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Eurofarma Ventures invests in
Stages Eurofarma Ventures invests in
Countries Eurofarma Ventures invests in
Investment Focus
Industry
- Biotechnology 5 (100%)
- Life Science 2 (40%)
- Therapeutics 2 (40%)
- Medical 1 (20%)
- Chemical 1 (20%)
Stage
- Series B 2 (40%)
- Seed 1 (20%)
- Series A 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- United States 4 (80%)
- Brazil 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Psivant Therapeutics
|
Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | Venture - Series Unknown / Jan 01, 2024 | |
gen-t
|
Gen-t is a platform capable of providing the map of genomic research. Gen-t was founded in 2021 and was headquartered in Sao Paulo, Brazil. | $1.3M / Seed / Oct 09, 2023 | |
Walden Biosciences
|
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. | Series B / Oct 01, 2023 | |
ROME Therapeutics
|
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. | $72M / Series B / Sep 12, 2023 | |
Abata Therapeutics
|
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases. | $95M / Series A / Jun 23, 2021 |
Co-Investors
Google Ventures
2 deals together
Third Rock Ventures
2 deals together
Alexandria Venture Investments
1 deal together
ATEM Capital Fund LP
1 deal together
Bristol-Myers Squibb
1 deal together
Casdin Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eurofarma Ventures invest in?
Eurofarma Ventures invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series B and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Eurofarma Ventures last invest?
The most recent investment recorded for Eurofarma Ventures closed in Jan 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
